Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | PPARD | Q03181 | 1/20 | 0.55 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.55 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42984 | 1.00 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL1131472 | 1.00 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL9216782 | 1.00 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL10786248 | 1.00 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL2830699 | 1.00 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL2829338 | 1.00 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL635007 | 1.00 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL26421 | 1.00 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL2895895 | 1.00 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL63654 | 1.00 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111533831-A | Method for removing residual metal after hydrogenation of unsaturated polymer | 浙江众立合成材料科技股份有限公司 | 2020-08-14 | — | — | CN | claimed |
| EP-0915898-B1 | CRYSTAL FORM I OF CLARITHROMYCIN | ABBOTT LAB (US) | 2003-12-03 | — | — | EP | claimed |
| EP-3839028-B1 | CLEANING PRODUCT | PROCTER & GAMBLE (US) | 2025-01-15 | — | — | EP | disclosed |
| EP-4386075-A2 | CLEANING PRODUCT | The Procter & Gamble Company (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11834627-B2 | Cleaning product | THE PROCTER & GAMBLE COMPANY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834629-B2 | Cleaning product | THE PROCTER & GAMBLE COMPANY (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4124651-B1 | CLEANING PRODUCT | PROCTER & GAMBLE (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-3450431-B1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | PTC THERAPEUTICS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11753604-B2 | Cleaning product | THE PROCTER & GAMBLE COMPANY (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230257680-A1 | CLEANING PRODUCT | THE PROCTER & GAMBLE COMPANY | 2023-08-17 | — | — | US | disclosed |
| EP-4227393-A1 | CLEANING PRODUCT | The Procter & Gamble Company (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20120130093-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | PTC THERAPEUTICS, INC. | 2012-05-24 | — | — | US | disclosed |
| US-8106223-B2 | Process for the production of alpha-tocotrienol and derivatives | EDISON PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-1920042-B1 | PARTICLES CONTAINING PERFUME HAVING IMPROVED FRAGRANCED PROPERTIES | HENKEL AG & CO KGAA (DE) | 2010-06-23 | — | — | EP | disclosed |
| US-20100105930-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | PTC THERAPEUTICS, INC. | 2010-04-29 | — | — | US | disclosed |
| EP-1920042-A1 | PARTICLES CONTAINING PERFUME HAVING IMPROVED FRAGRANCED PROPERTIES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2008-05-14 | — | — | EP | disclosed |
| US-20070225499-A1 | Process for the Preparation of 2,2-Disubstituted Pyrroles | MERCK & CO., INC. | 2007-09-27 | — | — | US | disclosed |
| WO-2007028478-A1 | PARTICLES CONTAINING PERFUME HAVING IMPROVED FRAGRANCED PROPERTIES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-03-15 | — | — | WO | disclosed |
| US-20050038074-A1 | Mitotic kinesin inhibitors | COLEMAN PAUL J (US) | 2005-02-17 | — | — | US | disclosed |
| US-4061651-A | Preparation of 3,5-disubstituted-4-nitroisoxazoles | TEXACO INC. (US) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225499-A1 | Process for the Preparation of 2,2-Disubstituted Pyrroles | KIF5B, KIF5A, KIF5C | GPR84 3501/4885FFAR1 4731/4885ACE2 2192/4885 |
| US-20120130093-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | TTPA, LCAT, PCTP | GPR84 2001/4885FFAR1 1547/4885ACE2 1422/4885 |
| US-20050038074-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | GPR84 3486/4885FFAR1 4845/4885ACE2 3875/4885 |
| US-20100105930-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | TTPA, LCAT, PCTP | GPR84 2001/4885FFAR1 1547/4885ACE2 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.